急性冠脉综合征合并睡眠呼吸暂停患者的心脏肌钙蛋白值:一项初步研究
该初步研究纳入89例OSA合并ACS患者与38例无OSA的ACS患者,从入院起每6小时采集血样检测cTnI直至连续两次呈下降趋势,取最高值为峰值cTnI。无OSA组峰值cTnI中位数10.7 ng/mL(IQR 1.78-40.1 ng/mL),显著高于OSA组的3.79 ng/mL(IQR 0.37-24.3 ng/mL),P=0.04。多变量线性回归分析显示,有无OSA对峰值cTnI有显著贡献,OSA组较无OSA组低54%。作者认为OSA在心肌梗死背景下可能有保护作用,OSA患者心肌损伤可能更轻,其心脏保护作用有待未来研究探索。
要点
- 在ACS患者中,无OSA组峰值cTnI中位数10.7 ng/mL(IQR 1.78-40.1 ng/mL)显著高于OSA组3.79 ng/mL(IQR 0.37-24.3 ng/mL),P=0.04。
- 多变量线性回归分析显示,有无OSA显著影响峰值cTnI水平,OSA组较无OSA组低54%。
- OSA组呼吸暂停低通气指数中位数32(IQR 20.8-46.6)/h,无OSA组为4.8(IQR 1.6-9.6)/h。
- 作者认为OSA在心肌梗死背景下可能有保护作用,OSA患者心肌损伤可能更轻。
- 作者建议未来研究应探索OSA在心脏保护中的可能作用。
适用人群与场景
- 因ACS入院并接受cTnI检测的患者,按有无OSA分为两组:OSA组89例,无OSA组38例。
诊断标准与关键阈值
- OSA组呼吸暂停低通气指数中位数32(IQR 20.8-46.6)/h,无OSA组4.8(IQR 1.6-9.6)/h。
处置流程与药物剂量
- 从入院时起每6小时采集血样检测cTnI,直至连续两次检测显示cTnI呈下降趋势;取最高值为峰值cTnI,用于估计梗死面积。
研究设计与关键结果
- 初步研究纳入89例OSA合并ACS患者和38例无OSA的ACS患者。
- 无OSA组峰值cTnI中位数10.7 ng/mL(IQR 1.78-40.1 ng/mL)vs OSA组3.79 ng/mL(IQR 0.37-24.3 ng/mL),P=0.04,无OSA组更高。
- 多变量线性回归分析(纳入峰值cTnI与患者分组、年龄、性别、ACS类型)显示,有无OSA显著贡献于峰值cTnI水平,OSA组较无OSA组低54%。
证据类型、等级与局限
- 证据类型:初步研究(pilot study)。
- 作者结论:OSA在心肌梗死背景下似乎有保护作用,OSA患者心肌损伤可能更轻;OSA在心脏保护中的可能作用应在未来研究中探索。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为OSA在心肌梗死背景下可能有保护作用,OSA患者心肌损伤可能更轻;作者建议未来研究探索OSA在心脏保护中的可能作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: An analysis of cardiac injury markers in patients with OSA who sustain an episode of acute coronary syndrome (ACS) may contribute to a better understanding of the interactions and impact of OSA in subjects with ACS. We compared peak cardiac troponin I (cTnI) levels in patients with OSA and patients without OSA who were admitted for ACS.
METHODS: Blood samples were collected every 6 hours from the time of admission until two consecutive assays showed a downward trend in the cTnI assay. The highest value obtained defined the peak cTnI value, which provides an estimate of infarct size.
RESULTS: We included 89 patients with OSA and 38 patients without OSA with an apnea-hypopnea index of a median of 32 (interquartile range [IQR], 20.8-46.6/h and 4.8 [IQR, 1.6-9.6]/h, respectively. The peak cTnI value was significantly higher in patients without OSA than in patients with OSA (median, 10.7 ng/mL [IQR, 1.78-40.1 ng/mL] vs 3.79 ng/mL [IQR, 0.37-24.3 ng/mL]; P = .04). The multivariable linear regression analysis of the relationship between peak cTnI value and patient group, age, sex, and type of ACS showed that the presence or absence of OSA significantly contributed to the peak cTnI level, which was 54% lower in patients with OSA than in those without OSA.
CONCLUSIONS: The results of this study suggest that OSA has a protective effect in the context of myocardial infarction and that patients with OSA may experience less severe myocardial injury. The possible role of OSA in cardioprotection should be explored in future studies.
参考来源
- Sánchez-de-la-Torre A, Soler X, Barbé F, et al. Cardiac Troponin Values in Patients With Acute Coronary Syndrome and Sleep Apnea: A Pilot Study. Chest. 2017. PMID: 28736306. doi:10.1016/j.chest.2017.06.046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。